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Background
Live attenuated vaccines against measles virus (MV) are
among of the safest vaccines and elicit long-term immu-
nity. Recombinant MVs that express foreign proteins at
different levels elicit significant immune responses and
protection against other pathogens in animal experi-
ments. Interestingly, all but one candidate bivalent vac-
cine tested by several other groups expressed a soluble
form of the foreign antigen. We ask here whether the sol-
uble, membrane-bound or other forms of the antigen pre-
sented by recombinant MVs is critical for the quality and
strength of the induced immune responses.
Methods
We report here the construction of soluble or stabilized
(i.e. non-shedding) forms of the envelope (Env) glycopro-
tein of simian immunodefiency virus SIV-smmPBj1.9, a
model strain for acute virus pathogenesis. To this end, the
Env protein was genetically truncated to express only the
Env protein ectodomain or its protease cleavage site was
modified to prevent cleavage and allow expression of
gp160-Env.
Results
Bivalent recombinant MVs encoding different forms and
levels of the SIVsmmPBj1.9 Env protein(s) were rescued,
successfully tested for SIV Env expression, and shown to
retain similar growth rates as parental MV with titers of up
to 1 × 108 TCID50/ml. These bivalent vaccines were inocu-
lated twice intraperitoneally in a prime-boost protocol
setting into transgenic IFNARko-CD46Ge mice (1 × 105
TCID50/dose). Transgenic CD46 expression allows MV
replication in the murine cells of these mice in vivo. We
are measuring the quality of the cellular and humoral
immune responses to different forms and amounts of the
SIV-smmPBj1.9 Env proteins presented by MV in mice.
Conclusion
These studies will be used to select optimal candidate
bivalent MV-SIV vaccines for the analysis of the immune
response and levels of protection in monkeys.
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